Expression ofSLC22A1variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib

Pretherapeutic Expression of the hOCT1 Gene Predicts a Complete Molecular Response to Imatinib Mesylate in Chronic-Phase Chronic Myeloid Leukemia

(2012) Luciana Nardinelli et al.   ACTA HAEMATOLOGICA

Genetic variants of organic cation transporter 1 (OCT1) and OCT2 significantly reduce lamivudine uptake

(2012) Min-Koo Choi et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance

(2012) Michael Heise et al.   BMC CANCER

Second-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to Sorafenib

(2012) A. Villanueva et al.   CLINICAL CANCER RESEARCH

Genetic Variants in Genes Involved in Mechanisms of Chemoresistance to Anticancer Drugs

(2012) J. J.G. Marin et al.   CURRENT CANCER DRUG TARGETS

No Correlation between the Expression of FXR and Genes Involved in Multidrug Resistance Phenotype of Primary Liver Tumors

(2012) P. Martinez-Becerra et al.   MOLECULAR PHARMACEUTICS

Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients

(2012) Linda Tarasova et al.   Pharmacogenetics and Genomics

Acquired resistance to drugs targeting receptor tyrosine kinases

(2011) Steven A. Rosenzweig   BIOCHEMICAL PHARMACOLOGY

Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma

(2011) Lars Henrik Jensen et al.   Expert Review of Anticancer Therapy

Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells

(2011) Hiroaki Sugiyama et al.   JOURNAL OF GASTROENTEROLOGY

Interactions of Tyrosine Kinase Inhibitors with Organic Cation Transporters and Multidrug and Toxic Compound Extrusion Proteins

(2011) T. Minematsu et al.   MOLECULAR CANCER THERAPEUTICS

DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma

(2011) Elke Schaeffeler et al.   Genome Medicine

Molecular Bases of Liver Cancer Refractoriness to Pharmacological Treatment

(2010) J. Marin et al.   CURRENT MEDICINAL CHEMISTRY

Role of Organic Cation Transporter 1, OCT1 in the Pharmacokinetics and Toxicity of cis-Diammine(pyridine)chloroplatinum(II) and Oxaliplatin in Mice

(2010) Shuanglian Li et al.   PHARMACEUTICAL RESEARCH

Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial

(2009) C Bengala et al.   BRITISH JOURNAL OF CANCER

Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Genes to Predict Response and Resistance to Imatinib Therapy in Chronic Myeloid Leukemia

(2009) D. H. Kim et al.   CLINICAL CANCER RESEARCH

Protein structure prediction on the Web: a case study using the Phyre server

(2009) Lawrence A Kelley et al.   Nature Protocols

OCT1 (SLC22A1) R61C polymorphism and response to imatinib treatment in chronic myeloid leukemia patients

(2008) Otto Zach et al.   LEUKEMIA & LYMPHOMA

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE